Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

• Status: Completed
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is looking at the mechanisms underlying the behavioral effects of ketamine in healthy and depressed individuals.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborators: American Psychiatric Association; National Institute of Mental Health (NIMH)
• Treatments: Ketamine

Criteria

Healthy Group

Inclusion Criteria:

• Male or female between the ages of 21-65 years.

• Able to provide written informed consent.

• Able to read and write English.

Exclusion Criteria:

• Personal or first-degree family member with history of mood, anxiety, or psychotic axis I DSM-IV disorders confirmed after comprehensive psychiatric evaluation.

• Any history of serious medical or neurological illness.

• Any signs of major medical or neurological illness on examination or as a result of ECG screening or laboratory studies.

• Lifetime history of psychoactive substance or alcohol dependence or substance or alcohol abuse (other than nicotine or caffeine abuse), or drinking more that 5 drinks/week during the last year.

• Abnormality on physical examination.

• A positive pre-study (screening) urine drug screen or, at the study physician's discretion on any drug screens given before the scans.

• Pregnant or lactating women or a positive urine pregnancy test for women of child-bearing potential at screening or prior to any imaging day.

• Subjects who test positive for HIV or viral hepatitis (hepatitis B and/or C)

• Has received either prescribed or over-the-counter (OTC) centrally active medicine or herbal supplements within the week prior to the MRI scan.

• Any history indicating learning disability, mental retardation, or attention deficit disorder.

• Known sensitivity to ketamine.

• Body circumference of 52 inches or greater.

• Body weight of 280 pounds or greater.

• History of claustrophobia.

• Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening questionnaire.

• Donation of blood in excess of 500 mL within 56 days prior to dosing.

• History of sensitivity to heparin or heparin-induced thrombocytopenia.

• Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate lower than 45/min or higher than 100/min.

Depression Group

Inclusion Criteria:

• Male or female between the ages of 21-65 years.

• Able to provide written informed consent.

• Current MDD Single Episode (296.2x) or Recurrent (296.3x), as determined by the Structured Clinical Interview for DSM-IV (SCID) patient edition

• Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher at baseline and start of first 13C-MRS.

• Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR16) score of 19 or higher at baseline and start of first 13C-MRS.

• No psychotropic medications for 2 or more weeks (4 weeks for Fluoxetine) prior to first 13C-MRS.

• Be able to understand and speak English.

Exclusion Criteria:

• Patients with a history of DSM-IV-TR diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder or currently exhibiting psychotic features associated with their depression; dementia or suspicion thereof, is also exclusionary.

• First-degree family member with history of schizophrenia or any other psychotic disorder.

• Serious suicide or homicide risk, as assessed by evaluating clinician; A serious suicide risk will be considered an inability to control suicide attempts, imminent risk of suicide in the investigator's judgment, or a history of serious suicidal behavior, which is defined using the Columbia-Suicide Severity Rating Scale (C-SSRS) as either (1) one or more actual suicide attempts in the 3 years before study entry with the lethality rated at 3 or higher, or (2) one or more interrupted suicide attempts with a potential lethality judged to result in serious injury or death.

• Substance abuse or dependence during the 12 months prior to screening.

• Any history of serious medical or neurological illness.

• Any signs of major medical or neurological illness.

• Abnormality on physical examination. A subject with a clinical abnormality may be included only if the study physician considers the abnormality will not introduce additional risk factors and will not interfere with the study procedure.

• A positive pre-study (screening) urine drug screen or on any drug screens given before the scans.

• Pregnant or lactating women or a positive urine pregnancy test for women of childbearing potential at screening or prior to any imaging day.

• Any history indicating learning disability, or mental retardation.

• Known sensitivity to ketamine.

• Body weight of 280 pounds or greater.

• History of claustrophobia.

• Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening questionnaire.

• Donation of blood in excess of 500 mL within 56 days prior to dosing.

• History of sensitivity to heparin or heparin-induced thrombocytopenia.

• Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate lower than 45/min or higher than 100/min.